Newsletter Tool

Today's Rundown

Game over: Bristol Myers, Nektar end $3.6B immuno-oncology program after 2 more late-stage flops
National Nurses United survey shows spikes in workplace violence, staffing issues remain
Bristol Myers settles HIV antitrust suit, but J&J, Gilead still await their day in court
Siemens Healthineers kicks off expansion plan by doubling size of Corindus HQ
U2 disbands: In a crushing step back, TG retracts FDA request for combo therapy due to death risk
Lawmakers blast McKinsey for 'serious conflict of interest' in opioid consulting
NEBGH launches guide for employers to address diabetes, obesity through an equity lens
FDA greenlights first breathalyzer test for COVID-19
10x Genomics debuts sample prep kits to expand access to single-cell research
DOJ probes Bausch over marketing, sales tactics for 4 meds: report
AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven
How to leverage artificial intelligence to combat inequities: McKinsey
Fujifilm lands $450M DOD contract to provide endoscopy tools, training to government hospitals

Featured Story

Game over: Bristol Myers, Nektar end $3.6B immuno-oncology program after 2 more late-stage flops

By Nick Paul Taylor

Bristol Myers Squibb and Nektar have read the last rites to their huge, failed cancer collaboration. With two more late-stage trials failing, the partners have ended clinical development of a combination they once saw as the future of immuno-oncology.

National Nurses United survey shows spikes in workplace violence, staffing issues remain

By Robert King

A new survey of registered nurses shows that incidents of workplace violence have spiked as well as increases in burnout at hospitals across the country.

Bristol Myers settles HIV antitrust suit, but J&J, Gilead still await their day in court

By Fraiser Kansteiner

The first of the three pharma juggernauts accused of monopolizing the market for HIV drugs is putting its legal woes to bed, courtesy of a settlement agreement under review at a federal court in California.

Siemens Healthineers kicks off expansion plan by doubling size of Corindus HQ

By Andrea Park

Less than three years after acquiring Corindus, Siemens Healthineers is moving the surgical robot maker from its longtime home in one Boston suburb to another.

U2 disbands: In a crushing step back, TG retracts FDA request for combo therapy due to death risk

By Max Bayer

TG Therapeutics is heading back to the drawing board after new data showed its cancer drug had an elevated risk of death, plucking Ukoniq off the market for the two indications it won accelerated approval for, in addition to withdrawing an approval request for a combo med.

Lawmakers blast McKinsey for 'serious conflict of interest' in opioid consulting

By Kevin Dunleavy

Global consulting firm McKinsey is under scrutiny from Congress after revelations that at least 22 employees who were consulting Purdue Pharma and other opioid producers were also doing work for government agencies tasked with regulating opioid use. The double-dipping represented a “serious conflict of interest,” according to a congressional report.

NEBGH launches guide for employers to address diabetes, obesity through an equity lens

By Paige Minemyer

Employers have long been focused on addressing obesity and diabetes in their workforces. However, COVID-19 is pushing them to think about these health challenges in new ways.

FDA greenlights first breathalyzer test for COVID-19

By Conor Hale

The portable breathalyzer developed by InspectIR Systems aims to deliver a result within three minutes by looking for the exhaled chemical compounds that can come with an infection.

10x Genomics debuts sample prep kits to expand access to single-cell research

By Conor Hale

They include methods to preserve fragile human tissues as well as a way to more easily access frozen samples.

DOJ probes Bausch over marketing, sales tactics for 4 meds: report

By Zoey Becker

Bausch Health is back in hot water, this time because the DOJ is reportedly investigating its marketing of four drugs.

AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven

By Gabrielle Masson

Some biotechs are building as others crumble, with several industry players–including AstraZeneca's Alexion and Arvinas involved in plans for a new 10-floor tower built for burgeoning biotechs.

How to leverage artificial intelligence to combat inequities: McKinsey

By Anastassia Gliadkovskaya

Two of the firm’s partners spoke at a Northwell Health event on AI in healthcare this week. In their panel, they provided many examples of how to harness AI to solve inequities while also cautioning against tech-driven bias.

Fujifilm lands $450M DOD contract to provide endoscopy tools, training to government hospitals